Locally advanced breast cancer (Q33654588)

28 July 2017

1 reference

title

Locally advanced breast cancer (English)

1 reference

28 July 2017

Esteva FJ

1

1 reference

28 July 2017

Hortobagyi GN

series ordinal

2

1 reference

28 July 2017

publication date

1 April 1999

1 reference

Hematology / Oncology Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

13

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

457-72, vii

1 reference

Treatment of locally advanced breast cancer without mastectomy. 5- and 10-year results of 135 tumors larger than 5 centimeters treated by external beam therapy, brachytherapy, and neoadjuvant chemotherapy

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Inflammatory breast carcinoma treated by radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Preoperative chemotherapy induces apoptosis in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Management of inflammatory carcinoma of the breast. A combined modality approach

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Multimodal treatment of locoregionally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Primary chemotherapy for early and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Inflammatory breast cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Vinorelbine: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Aggressive combined modality therapy for advanced local-regional breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Kinetic concepts in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Prednisolone improves the response to primary endocrine treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Surgical adjuvant chemotherapy of metastatic murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

Initial chemoimmunotherapy in inflammatory carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970065-4

7 January 2021

10.1016/S0889-8588(05)70065-4

Identifiers

DOI

1 reference

28 July 2017

1 reference